Merck, FDA Dispute Safety Reviewer’s Estimate Of Vioxx-Related Events
Executive Summary
It is not possible to estimate the number of cardiovascular adverse events caused by Vioxx based on the data currently available, Merck CEO Ray Gilmartin maintained during the Nov. 18 Senate Finance Committee hearing on the drug's withdrawal